Yahoo
NYSE - Nasdaq Real Time Price USD

Annovis Bio, Inc. (ANVS)

0.8660 +0.0211 (+2.50%)
As of 1:32:04 PM EST. Market Open.
Chart Range Bar
Loading chart for ANVS
  • Previous Close 0.8449
  • Open 0.9395
  • Bid 0.8887 x 80000
  • Ask 0.8892 x 170000
  • Day's Range 0.8303 - 0.9900
  • 52 Week Range 0.6200 - 5.5000
  • Volume 4,080,254
  • Avg. Volume 1,592,429
  • Market Cap (intraday) 37.258M
  • Beta (5Y Monthly) 1.35
  • PE Ratio (TTM) --
  • EPS (TTM) -1.7500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 10.50
  • Moby Rating Neutral

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

www.annovisbio.com

7

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANVS
75.05%
S&P 500 (^GSPC)
10.24%

1-Year Return

ANVS
56.84%
S&P 500 (^GSPC)
12.15%

3-Year Return

ANVS
85.09%
S&P 500 (^GSPC)
73.59%

5-Year Return

ANVS
97.31%
S&P 500 (^GSPC)
61.07%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -17.61M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

7.00
10.50 Average
0.8660 Current
17.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/28/2026
Analyst Roth Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 8 -> 7

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -142.36%

  • Return on Equity (ttm)

    -703.68%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -49.52M

  • Diluted EPS (ttm)

    -1.7500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.73M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -23.79M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: